ArticleBehavioral and brain functions : BBF2026
Astrocyte-derived IL-17A facilitates angiogenesis following ischemia-like injury via an IL-6-dependent STAT3-VEGF signaling cascade.
Article in Behavioral and brain functions : BBF, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAngiogenesis plays a vital role in cerebral tissue repair following ischemic stroke. Prior in vivo studies have identified astrocytic interleukin-17A (IL-17A) as a critical mediator of post-ischemic angiogenesis, associated with upregulation of interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF). However, the intracellular signaling mechanisms underlying these effects within astrocytes have not been fully elucidated. This study delineates a specific intracellular signaling mechanism through which astrocytic IL-17A promotes angiogenesis following an in vitro ischemia-like injury.
methodsPrimary astrocytes were exposed to oxygen-glucose deprivation followed by reperfusion (OGD/R). Astrocyte viability was assessed using the Cell Counting Kit-8 assay. Brain microvascular endothelial cells (BMECs) were cultured with astrocyte-conditioned medium (ACM). Astrocytes were treated with recombinant IL-17A (rIL-17A), IL-17A-targeted small interfering RNA, a neutralizing antibody against IL-6, or the Janus Kinase 2/Signal Transducer and Activator of Transcription 3 (JAK2/STAT3) pathway inhibitor AG490. Protein levels were quantified, and angiogenic capacity was determined via tube formation assays and CD34 expression analysis.
resultsExposure to OGD/R increased IL-17A secretion from astrocytes. Treatment with rIL-17A enhanced astrocyte viability and induced IL-6 production. Activation of the JAK2/STAT3 pathway by IL-6 was required for the subsequent VEGF upregulation. Consequently, ACM from rIL-17A-treated astrocytes significantly promoted angiogenic activity in BMECs, as evidenced by enhanced tube formation. These pro-angiogenic effects were significantly attenuated by IL-17A knockdown, IL-6 neutralization, or inhibition of JAK2/STAT3 signaling in astrocytes.
conclusionsThis study delineates a specific intracellular signaling mechanism through which astrocytic IL-17A promotes angiogenesis following ischemia-like injury. The findings identify an IL-6-dependent activation of the STAT3-VEGF signaling axis as a key mediator of this process, underscoring the therapeutic potential of targeting astrocytic IL-17A signaling in post-stroke angiogenic repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.